tbuckley/cabot-search huggingface dataset:
Die Goldbehandlung der chronischen Arthritis unter besonderer Berücksichtigung der Komplikationen
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
VASCULAR CHANGES IN CHRONIC PEPTIC ULCERS
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SPECIAL FEATURE
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Stedman's Medical Dictionary of Words Used in Medicine and Their Derivations and Pronunciation Including Dental, Veterinary, Chemical, Botanical, Electrical, Life Insurance and Other Special Terms; Anatomical Tables of Titles in General Use, the Terms Sanctioned by the Basle Anatomical Convention; the New British Anatomical Nomenclature; Pharmaceutical Preparations Official in the U. S. and British Pharmacopœias or Contained in the National Formulary; Biographical Sketches of the Principal …
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The burden of hepatitis C in the United States
Authors: Ray W. Kim
Journal: Hepatology (2002)

According to the third National Health and Nutrition Examination Survey (NHANES), 3.9 million of the U.S. civilian population have been infected with hepatitis C virus (HCV), of whom 2.7 million (74%) have chronic infection. Hepatitis C virus infection is most common among non-Caucasian men, ages 30 to 49 years. Moreover, the prevalence of antibody to hepatitis C virus in groups not represented in the NHANES sample, such as the homeless or incarcerated, may be as high as 40%. The age-adjusted death rate for non-A, non-B viral hepatitis increased from 0.4 to 1.8 deaths per 100,000 persons per year between 1982 and 1999. In 1999, the first year hepatitis C was reported separately, there were 3,759 deaths attributed to HCV, although this is likely an underestimate. There was a 5-fold increase in the annual number of patients with HCV who underwent liver transplantation between 1990 and 2000. Currently, more than one third of liver transplant candidates have HCV. Inpatient care of HCV-related liver disease has also been increasing. In 1998, an estimated 140,000 discharges listed an HCV-related diagnosis, accounting for 2% of discharges from non-federal acute care hospitals in the United States. The total direct health care cost associated with HCV is estimated to have exceeded $1 billion in 1998. Future projections predict a 4-fold increase between 1990 and 2015 in persons at risk of chronic liver disease ( i.e. , those with infection for 20 years or longer), suggesting a continued rise in the burden of HCV in the United States in the foreseeable future. (Hepatology 2002;36:S30-S34).
Protein Targeting in the Neuron
Authors: G. Regis B. Kelly and Eric
Journal: Annual Review of Neuroscience (1993)

The brain's default mode network consists of discrete, bilateral and symmetrical cortical areas, in the medial and lateral parietal, medial prefrontal, and medial and lateral temporal cortices of the human, nonhuman primate, cat, and rodent brains. Its ...Read More
La qualité de vie à long terme après myotomie endoscopique par voie orale reste compromise chez les patients avec une achalasie de type III
Journal: Endoscopy (2017)

La myotomie endoscopique du pylore (POEM) s’impose progressivement comme le nouveau traitement de référence de l’achalasie. Les récentes recommandations américaines (Kahrilas P.J., Gastroenterology 2017) recommandent le POEM au même niveau d’efficacité et de risques que la myotomie chirurgicale selon Heller pour les achalasies de type I et II; le POEM est recommandé en première intention dans l’achalasie de type III. Les données de la littérature indiquent une efficacité clinique et manométrique supérieure à 90 % du POEM, comparable à l’intervention de Heller. Cette étude monocentrique mexicaine, réalisée dans un centre tertiaire, s’intéresse à la qualité de vie avant et après POEM pour achalasie, utilisant le questionnaire “AE-18”.
Abstract 1200: AXL targeting enhances lymphocyte-mediated cytotoxicity of lung cancer cells
Authors: Sallem Chouaib, Stephane Terry, Stephanie Buart, Agnete Engelsen, Gro Gausdal, James Lorens, Jean Paul Thiery, Fathia Mami-Chouaib
Journal: Cancer Research (2019)

Abstract As immunotherapies are now used to treat a large proportion of NSCLC patients, defining mechanisms of immune resistance is critical. Immune resistance may arise from both genetic instability and tumor heterogeneity driven by microenvironmental stresses such as hypoxia that promotes carcinoma cell plasticity as well as extrinsic or intrinsic mechanisms of immune resistance. AXL, a member of the TAM receptor tyrosine kinase family is widely expressed human cancers and increasingly recognized for its role in cell plasticity and drug resistance. In this study, we used a model of hypoxia-induced tumor plasticity to generate multiple lung cancer clones with mesenchymal and epithelial features to address mechanisms of immune resistance. We demonstrate that AXL expression is dramatically increased in mesenchymal lung cancer clones. Moreover, expression of AXL in the cells was correlated with an increased cancer cell intrinsic resistance to both NK and CTL-mediated killing, Notably, small molecule AXL targeting potently sensitized mesenchymal lung cancer cells to cytotoxic lymphocyte-mediated killing. Mechanistically, we showed that attenuation of AXL-dependent immune resistance to immune cells involved a novel molecular network comprising NF-κB activation, increased ICAM1 expression, and upregulation of ULBP1 expression coupled with MAPK inhibition. Congruently, higher ICAM1 and ULBP1 tumor expression, correlated with improved patient survival in two NSCLC cohorts. These results reveal a novel AXL-mediated immune escape regulatory pathway, suggest AXL as a novel candidate biomarker for tumor resistance to NK and CTL immunity, and support AXL targeting to optimize immune response in NSCLC. Citation Format: Sallem Chouaib, Stephane Terry, Stephanie Buart, Agnete Engelsen, Gro Gausdal, James Lorens, Jean Paul Thiery, Fathia Mami-Chouaib. AXL targeting enhances lymphocyte-mediated cytotoxicity of lung cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1200.
HBV specific ImmTAV induce a broad immune response enabling the elimination of HBV positive cells
Authors: Sarah Leonard, Rachel Paterson, Mauro Monteiro, Joannah Fergusson, David Depoil, Mary Connolly, Sara Crespillo Torreno, Marcin Dembek, Jose Donoso, Tressan Grant, Dominic Hine, Richard Suckling, Zoë Wallace, Andrew Knox, Ruth Martinez Hague, Bethany Turner, Katrin Wiederhold, Stephen Megit, Lucy Dorrell
Journal: Journal of Hepatology (2020)
Book Review Roentgen Treatment of Diseases of the Nervous System . By Cornelius G. Dyke, M.D., and Leo M. Davidoff, M.D. 8°, cloth, 198 pp., with 12 engravings, 7 charts and 16 graphs. Philadelphia: Lea and Febiger, 1942. $3.25.
Journal: New England Journal of Medicine (1943)
444PD Patient-reported outcomes (PROs) in ASCEND-5: A randomized, phase 3 study of ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase rearranged (ALK+) NSCLC previously treated with CT and crizotinib (CRZ)
Authors: T.S.K. Mok, G. Scagliotti, T.M. Kim, L. Crinò, G. Liu, C. Gridelli, S. Novello, K. Kiura, A. Bearz, O. Gautschi, E. Felip, M. Nishio, D.R. Spigel, P. Urban, S. Deudon, C. Zheng, A.T. Shaw
Journal: Annals of Oncology (2016)
American Society of Nephrology 28th annual meeting. November 5-8, 1995. Abstracts.
Journal: Journal of the American Society of Nephrology (1995)

Log in or Register Subscribe to journalSubscribe Get new issue alertsGet alerts Enter your Email address: Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy. Subscribe to eTOC Secondary Logo Journal Logo All Articles Images Videos Podcasts Blogs Advanced Search Toggle navigation Subscribe Register Login Articles Current IssuePublished Ahead of Print Subject CollectionsPodcastsArchives Authors Submit to JASNInformation for Authors Journal Info About JASNEditorial TeamEditorial FellowsEditorial Fellowship ApplicationJASN ImpactJASN Recognizes More AlertsAdvertisingSubscriptionsReprints All Articles Images Videos Podcasts Blogs Advanced Search
Alcoholism and alcoholic organ damage and genetic polymorphisms of alcohol metabolizing enzymes in Chinese patients
Authors: Y Chao
Journal: Hepatology (1997)

It is still not clear why some alcoholic patients acquire certain organ-specific complications of alcoholism whereas other alcoholic patients acquire different ones. As we know the liver alcohol dehydrogenase (ADH), aldehyde dehydrogenase (ALDH), and cytochrome P4502E1 (P4502E1) are polymorphic at the ADH2, ADH3, and ALDH2 loci and the 5′-flanking region of the P4502E1. The aim of this study was to investigate the differences between Chinese alcoholic patients with cirrhosis and acute pancreatitis by studying the genetic polymorphisms of ADH2, ADH3, ALDH2, and P4502E1. Genotyping of ADH2, ADH3, ALDH2, and P4502E1 was performed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methods on peripheral white blood cell DNA from 75 alcoholic cirrhotic patients, 48 acute alcoholic pancreatitis patients, 19 heavy drinkers without liver disease or pancreatitis, and 235 controls. The results showed that the frequencies of the alleles ADH2*1 and ALDH2*1 in the alcoholic cirrhotic patients were significantly higher than those in the nonalcoholic controls. In acute alcoholic pancreatitis patients, only the frequency of allele ALDH2*1, not ADH2*1 was significantly higher than in the nonalcoholic controls. The allele frequency of ADH2*1 in acute pancreatitis patients was significantly lower (P < .01) than in alcoholic cirrhotic patients. The daily amount of alcohol consumption was significantly lower in patients with acute pancreatitis than in patients with cirrhosis (P < .0005). The genotype distributions of P4502E1, detected by RsaI and PstI, were not different among alcoholic cirrhotic patients, alcoholic pancreatitis patients, heavy drinker, and nonalcoholic controls. In conclusion, ALDH2*1 is the most important alcohol metabolizing gene affecting predisposition to alcoholism whereas the ADH2*2 gene may influence susceptibility to acute alcoholic pancreatitis. The patients with alcohol-induced cirrhosis and with alcohol-induced acute pancreatitis are of two different subpopulations.
Brittle Diabetes
Authors: J. David Schnatz
Journal: JAMA (1986)

This book is edited by a prominent British diabetologist, with an array of expert contributors: 36 Europeans (including 15 from the United Kingdom) and seven Americans. It deals with a relatively uncommon problem as it affects the broad range of diabetic patients, but has been compiled because of the "enormous burden" these patients place on the health care system, their families, and themselves. After an introduction (12 pages), there are three major sections: the clinical problem (27 pages), pathogenesis (131 pages), and treatment approaches (117 pages). The book should have broad appeal, since there are features relevant to a variety of interests. From the clinical standpoint, the early chapters describe the nature of the problem in children and young adults. A pattern is described of young patients, predominantly female, often overweight, who have frequent episodes of diabetic ketoacidosis and high subcutaneous insulin requirements. One is reminded of the uncertainty of
Parenthood in survivors of Hodgkin lymphoma: An EORTC-GELA general population case-control study.
Authors: M. A. E. van der Kaaij, N. Heutte, P. Meijnders, J. M. M. Raemaekers, E. Abeilard-Lemoisson, A. Allgeier, B. Meulemans, A. H. M. Simons, N. Mounier, M. Henry-Amar, J. C. Kluin-Nelemans
Journal: Journal of Clinical Oncology (2011)

9062 Background: We investigated the impact of Hodgkin lymphoma (HL) on parenthood, comparing HL survivors with matched general population controls (UNECE Generations and Gender Survey), available for France and The Netherlands. Methods: Surviving and traceable patients treated in 1964-2004 in 9 successive multicenter clinical trials were sent a life style questionnaire in 2009, including questions on parenthood. Responders aged ≥15 at treatment were matched (1:3-4) for sex, country, education and year of birth (grouped per 10 years). Controls were given an artificial date of start of treatment, the same as their matched patient. The main endpoint was presence of biological children after treatment, evaluated using conditional logistic regression analysis. Results: Of 3,604 patients contacted in 5 countries, 1,910 (53.0%) responded. 1,654 French (737) and Dutch (917) patients were matched with 6,414 controls. Median follow-up was 14 (range 5-44) years. Before treatment, 45.7% of patients and 48.8% of controls had children. After treatment, the odds ratio (OR) to have children was 0.77 (95% CI 0.68-0.87; p<0.001) for patients compared to controls. OR did not change with correction for presence of children before, age at start of or treatment period. OR was 0.84 (95% CI 0.70-1.00; p=0.06) for males; it was 0.64 (95% CI 0.52-0.77; p<0.001) for females corrected for age at start of treatment. Of 898 patients childless before treatment, 60.1% tried to have children and 46.7% succeeded, compared to 49.3% in 3196 childless controls (OR=0.87; 95% CI 0.74-1.01, p=0.08). Among 756 patients with children before treatment 16.8% attempted post-treatment parenthood; 12.4% succeeded compared to 22.2% of 3218 controls with children before treatment (OR=0.49; 95% CI 0.38-0.63, p<0.001). Post-treatment adoption concerned 26 patients (1.6%) compared to overall adoption in 59 controls (0.9%) (OR 1.78; 95% CI 1.10-2.87; p=0.02). Conclusions: Survivors of Hodgkin lymphoma had slightly but significantly less children after treatment than general population controls. The difference only concerned patients who had children before treatment. Remarkably, three-quarters of patients succeeded who attempted post-treatment parenthood.
Anti-B Isohemagglutinins in the Serum of a Patient with a Weak Red Cell B Antigen
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply
Authors: Kai Breuhahn, Gregory Gores, Peter Schirmacher
Journal: Hepatology (2011)

The intention of the review was to provide some integrative overview about the many molecular studies, especially profiling analyses, relating to the various molecular alterations that occur during HCC development and how they may, or should, impact on novel approaches to diagnosis and therapy. We neither addressed epidemiology nor prevention. Nevertheless, there is no question that hepatitis B and C viruses are the main etiologies, and they are by no means eradicated by vaccination or antiviral treatment.2 In addition, HCC is epidemic where neither alcohol, tobacco, nor obesity and diabetes represent a significant factor. Knowledge about predictive molecular markers needs more than an ignorant Medline search. Clinical oncology has integrated many predictive markers—breast cancer (ER [estrogen receptor], PR [progesterone receptor], HER2/ERBB2/NEU), non–small-cell lung cancer (epidermal growth factor receptor mutations), gastric cancer (HER2/ERBB2/NEU), gastrointestinal stromal tumor (KIT) to name a few and many more (BRAF, ELM4-ALK, and others) to come soon. We are sure that testing for these markers is also available to French cancer patients. Of course, it could always be better, but there is significant funding and research in epidemiology and prevention of cancer. Those who understand the topic know that molecular cancer research is not an opponent but a friend and significant driver of cancer epidemiology and prevention (and of course vice versa), which holds true also specifically in HCC. Otherwise, without molecular research, how would we know about hepatitis B virus, how it causes HCC, and that this can be prevented by vaccination3; or read the seminal articles about specific p53 mutations caused by aflatoxins, a paradigm of molecular cancer epidemiology4, 5; and…much more to come. Kai Breuhahn Ph.D.*, Gregory Gores M.D. , Peter Schirmacher Ph.D.*, * Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany, Mayo Medical School, Mayo Clinic College of Medicine, Rochester, MN.
DISCRIMINATION BETWEEN EFFECTS OF DISEASE AND INJURY.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal